NASDAQ:BFRA - Biofrontera Stock Price, Price Target & More

$14.00 -0.08 (-0.57 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$14.08
Today's Range$14.00 - $14.53
52-Week Range$11.25 - $17.98
Volume300 shs
Average Volume1,278 shs
Market Capitalization$309.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Biofrontera (NASDAQ:BFRA)

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin. The company is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Receive BFRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BFRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BFRA
CUSIPN/A
Phone49-02-1487-6320

Debt

Debt-to-Equity Ratio2.63%
Current Ratio5.50%
Quick Ratio4.40%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.78 million
Price / Sales45.68
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees125
Outstanding Shares22,120,000

How to Become a New Pot Stock Millionaire

Biofrontera (NASDAQ:BFRA) Frequently Asked Questions

What is Biofrontera's stock symbol?

Biofrontera trades on the NASDAQ under the ticker symbol "BFRA."

When is Biofrontera's next earnings date?

Biofrontera is scheduled to release their next quarterly earnings announcement on Friday, May, 18th 2018. View Earnings Estimates for Biofrontera.

What price target have analysts set for BFRA?

1 equities research analysts have issued twelve-month target prices for Biofrontera's stock. Their forecasts range from $19.00 to $19.00. On average, they anticipate Biofrontera's share price to reach $19.00 in the next year. View Analyst Ratings for Biofrontera.

Who are some of Biofrontera's key competitors?

Who are Biofrontera's key executives?

Biofrontera's management team includes the folowing people:
  • Prof. Hermann Lübbert, Co-Founder, Chairman of Management Board & CEO (Age 62)
  • Mr. Thomas Schaffer, CFO & Member of Management Board (Age 55)
  • Mr. Christoph Dünwald, Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board (Age 50)

When did Biofrontera IPO?

(BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

When did the company's quiet period expire?

Biofrontera's quiet period expired on Monday, March 26th. Biofrontera had issued 1,215,000 shares in its IPO on February 14th. The total size of the offering was $12,004,200 based on an initial share price of $9.88. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Has Biofrontera been receiving favorable news coverage?

News articles about BFRA stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biofrontera earned a media sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the company an impact score of 45.62 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Biofrontera?

Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biofrontera's stock price today?

One share of BFRA stock can currently be purchased for approximately $14.00.

How big of a company is Biofrontera?

Biofrontera has a market capitalization of $309.72 million and generates $6.78 million in revenue each year. The company earns $-11,700,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Biofrontera employs 125 workers across the globe.

How can I contact Biofrontera?

Biofrontera's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 49-02-1487-6320 or via email at [email protected]


MarketBeat Community Rating for Biofrontera (BFRA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  20
MarketBeat's community ratings are surveys of what our community members think about Biofrontera and other stocks. Vote "Outperform" if you believe BFRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BFRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biofrontera (NASDAQ:BFRA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Biofrontera in the last 12 months. Their average twelve-month price target is $19.00, suggesting that the stock has a possible upside of 35.71%. The high price target for BFRA is $19.00 and the low price target for BFRA is $19.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.00$19.00N/AN/A
Price Target Upside: 35.71% upsideN/AN/AN/A

Biofrontera (NASDAQ:BFRA) Consensus Price Target History

Price Target History for Biofrontera (NASDAQ:BFRA)

Biofrontera (NASDAQ:BFRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018BenchmarkInitiated CoverageBuy$19.00HighView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Biofrontera (NASDAQ:BFRA) Earnings History and Estimates Chart

Earnings by Quarter for Biofrontera (NASDAQ:BFRA)

Biofrontera (NASDAQ:BFRA) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.3 EPS
Next Year EPS Consensus Estimate: $-0.31 EPS

Biofrontera (NASDAQ BFRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/18/2018        
11/26/2017Q3 2017($0.30)$2.74 millionViewN/AView Earnings Details
8/31/2017Q2 2017($0.28)$2.63 millionViewN/AView Earnings Details
5/19/2017Q1 2017($0.19)$2.79 millionViewN/AView Earnings Details
4/3/2017Q4 2016($0.24)$3.51 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Biofrontera (NASDAQ:BFRA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Biofrontera (NASDAQ BFRA) Insider Trading and Institutional Ownership History

Insider Trading History for Biofrontera (NASDAQ:BFRA)

Biofrontera (NASDAQ BFRA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Biofrontera (NASDAQ BFRA) News Headlines

Source:
DateHeadline
Biofrontera (BFRA) Downgraded to "Sell" at ValuEngineBiofrontera (BFRA) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 10 at 1:04 AM
Biofrontera AGs Quiet Period Set To End  on March 26th (NASDAQ:BFRA)Biofrontera AG's Quiet Period Set To End on March 26th (NASDAQ:BFRA)
www.americanbankingnews.com - March 19 at 1:54 AM
Benchmark Initiates Coverage on Biofrontera (BFRA)Benchmark Initiates Coverage on Biofrontera (BFRA)
www.americanbankingnews.com - March 9 at 8:08 PM
Biofrontera AG (BFRA) to Raise $18 Million in IPOBiofrontera AG (BFRA) to Raise $18 Million in IPO
www.americanbankingnews.com - February 10 at 1:18 AM

SEC Filings

Biofrontera (NASDAQ:BFRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Biofrontera (NASDAQ BFRA) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.